BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33213472)

  • 21. Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations.
    Liegl B; Gülly C; Reich O; Nogales FF; Beham A; Regauer S
    Histopathology; 2007 Mar; 50(4):448-52. PubMed ID: 17448020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study.
    Yoshino T; Muro K; Yamaguchi K; Nishina T; Denda T; Kudo T; Okamoto W; Taniguchi H; Akagi K; Kajiwara T; Hironaka S; Satoh T
    EBioMedicine; 2015 Apr; 2(4):317-23. PubMed ID: 26137573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma.
    Ishige T; Itoga S; Sato K; Kitamura K; Nishimura M; Sawai S; Matsushita K; Suzuki K; Ota S; Miyauchi H; Matsubara H; Nakatani Y; Nomura F
    Clin Biochem; 2014 Dec; 47(18):340-3. PubMed ID: 25262986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
    Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
    BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical assay for detection of K-ras protein expression in metastatic colorectal cancer.
    Elsabah MT; Adel I
    J Egypt Natl Canc Inst; 2013 Mar; 25(1):51-6. PubMed ID: 23499207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Screening for K-ras mutations in colorectal and lung cancers by using a novel real-time PCR with ADx-K-ras kit and Sanger DNA sequencing].
    Zhang HP; Fu L; Chen PQ; Ye YB; Ji TH; Zheng LM
    Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):757-61. PubMed ID: 21215167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-time PCR-based method for the rapid detection of extended RAS mutations using bridged nucleic acids in colorectal cancer.
    Iida T; Mizuno Y; Kaizaki Y
    Clin Chim Acta; 2019 Feb; 489():164-168. PubMed ID: 29111094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
    Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tyrosine kinase receptor status in endometrial stromal sarcoma: an immunohistochemical and genetic-molecular analysis.
    Cossu-Rocca P; Contini M; Uras MG; Muroni MR; Pili F; Carru C; Bosincu L; Massarelli G; Nogales FF; De Miglio MR
    Int J Gynecol Pathol; 2012 Nov; 31(6):570-9. PubMed ID: 23018215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians.
    Malhotra P; Anwar M; Nanda N; Kochhar R; Wig JD; Vaiphei K; Mahmood S
    Tumour Biol; 2013 Jun; 34(3):1901-11. PubMed ID: 23526092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy.
    Oltedal S; Aasprong OG; Møller JH; Kørner H; Gilje B; Tjensvoll K; Birkemeyer EM; Heikkilä R; Smaaland R; Nordgård O
    Int J Colorectal Dis; 2011 Oct; 26(10):1271-7. PubMed ID: 21573767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.
    Rotella V; Fornaro L; Vasile E; Tibaldi C; Boldrini L; Chella A; D'Incecco A; Cirigliano G; Chioni A; Lupi C; Sensi E; Ginocchi L; Giovannelli S; Pennucci MC; Fontanini G; Baldini E
    J Exp Clin Cancer Res; 2014 Oct; 33(1):77. PubMed ID: 25300933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
    Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
    Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
    Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
    Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
    [No Abstract]   [Full Text] [Related]  

  • 38. Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach.
    Carotenuto P; Roma C; Rachiglio AM; Tatangelo F; Pinto C; Ciardiello F; Nappi O; Iaffaioli RV; Botti G; Normanno N
    Pharmacogenomics; 2010 Aug; 11(8):1169-79. PubMed ID: 20712532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer.
    Isnaldi E; Garuti A; Cirmena G; Scabini S; Rimini E; Ferrando L; Lia M; Murialdo R; Tixi L; Carminati E; Panaro A; Gallo M; Grillo F; Mastracci L; Repetto L; Fiocca R; Romairone E; Zoppoli G; Ballestrero A
    J Transl Med; 2019 Apr; 17(1):137. PubMed ID: 31036005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of RASSF1A expression in colorectal cancer and its association with K-ras status.
    Cao D; Chen Y; Tang Y; Peng XC; Dong H; Li LH; Cheng K; Ge J; Liu JY
    Biomed Res Int; 2013; 2013():976765. PubMed ID: 23865079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.